Analysis of the TCGA and GTEx databases revealed that SREBF1 expression is significantly increased in bladder urothelial carcinoma (BLCA) (P < 0.01), breast invasive carcinoma (BRCA), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), esophageal carcinoma (ESCA), HNSC, kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), brain lower grade glioma (LGG), pancreatic adenocarcinoma (PAAD), stomach adenocarcinoma (STAD), and thymoma (THYM) (P < 0.001) tumors compared with adjacent normal tissues (Fig. 1A). Here, SREBF1 is linked to diffuse large B-cell lymphoma.